Titan Pharmaceuticals has announced that the FDA has granted fast track designation for Spheramine for the treatment of advanced Parkinsons disease. Spheramine consists of normal, human retinal pigment epithelial cells adhered to spherical microscopic carriers.
In the Pipeline
- Titan Pharmaceuticals has announced that the FDA has granted fast track designation for Spheramine for the treatment of advanced Parkinson’s disease. Spheramine consists of normal, human retinal pigment epithelial cells adhered to spherical microscopic carriers.
- Peninsula Pharmaceuticals has announced that patient enrollment has begun in the final Phase III trial of its lead product candidate, doripenem. Doripenem, a broad-spectrum antibiotic, is a new member of the carbapenem class of beta-lactam antibiotics. This trial will compare the safety and efficacy of intravenous doripenem with that of intravenous imipenem in patients with ventilator-associated pneumonia.
- PTC Therapeutics has announced the initiation of a Phase I clinical trial of PTC124 to evaluate the drug’s safety, tolerability, and pharmacokinetic profile. PTC124 is a small-molecule drug that is being investigated initially as a treatment for cystic fibrosis and Duchenne muscular dystrophy.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.